Search Results

Press Releases

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

November 27, 2024

·

4 min read

Business

Saniona publishes its year-end report for 2021

Saniona received SEK 7.3 million (US$0.8 million) from Novartis related to Novartis’s January 2021 acquisition of Cadent Therapeutics, in which Saniona held a 3% ownership stake.

February 24, 2022

·

4 min read

Business

Saniona publishes its interim report for the third quarter of 2021

Saniona achieved orphan drug designation (ODD) from the FDA for Tesomet for the treatment of hypothalamic obesity (HO).

November 18, 2021

·

3 min read

Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team

Saniona, a clinical-stage biopharmaceutical company focused on rare diseases, announced that it will refocus its strategy on ion channel research and development and, as a result, further streamline its operations.

April 25, 2022

·

10 min read

Drug Development

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity

Saniona announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity.

November 17, 2021

·

6 min read

Business

Saniona appoints Wendy Dwyer as Chief Business Officer

Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announced the appointment of Wendy Dwyer as Chief Business Officer.

September 15, 2021

·

3 min read

Business

Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market

Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announcedthat the Chairman and the CEO, as well as additional members of the Board of Directors and executive management team, have purchased 82,000 shares of the company in the open market for a total value of approximately SEK 861,182.

December 2, 2021

·

2 min read

Drug Development

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona announced that it has dosed the first patientin a Phase 1 clinical trial of SAN711,a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine.SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 receptors and may be applicable in the treatment of rare neuropathic disorders.

June 30, 2021

·

3 min read

Drug Development

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).

December 28, 2021

·

7 min read

Business

Saniona appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee

Saniona today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders’ meeting held on September 16, 2021

September 16, 2021

·

3 min read